JSM 6427

Drug Profile

JSM 6427

Alternative Names: JSM-6427

Latest Information Update: 04 Mar 2011

Price : $50

At a glance

  • Originator Jerini Ophthalmic
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Proliferative vitreoretinopathy

Most Recent Events

  • 04 Mar 2011 Development discontinued for Age-related macular degeneration during 2010
  • 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations, including JSM 6427 for the treatment of age-related macular degeneration
  • 07 Dec 2007 Jerini Ophthalmic enters into a research collaboration agreement with University College London Institute of Ophthalmology for the development of JSM 6427 in age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top